EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeted Next Generation Sequencing molecular profiling and its clinical application in adrenocortical cancer

Francesca Cioppi, Giulia Cantini, Tonino Ercolino, Massimiliano Chetta, Lorenzo Zanatta, Gabriella Nesi, Massimo Mannelli, Mario Maggi, Letizia Canu iD, Michaela Luconi iD

European Journal of Endocrinology · 02.07.2024 · 191 (1) · 17-30

DOI: 10.1093/ejendo/lvae077 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Endocrinology, erschienen am 02.07.2024. Verfasst von Francesca Cioppi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Medicine, University of Florence, 50139 Florence, Italy. Hauptthemen laut MEDLINE: Adrenal Cortex Neoplasms, High-Throughput Nucleotide Sequencing, Adrenocortical Carcinoma. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Italian Ministry of University and Research, PRIN program, Progetti di Ricerca di Rilevante Interesse Nazionale 2022.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Adrenal cortical carcinoma (ACC) is a rare malignancy with a generally poor but heterogeneous prognosis, especially depending on the tumour stage at diagnosis. Identification of somatic gene alterations combined with clinical/histopathological evaluation of the tumour can help improve prognostication. We applied a simplified targeted-Next-Generation Sequencing (NGS) panel to characterise the mutational profiles of ACCs, providing potentially relevant information for better patient management. Design and methods Thirty frozen tumour specimens from a local ACC series were retrospectively analysed by a custom-NGS panel (CDKN2A, CTNNB1, DAXX, MED12, NF1, PRKAR1A, RB1, TERT, TP53, ZNRF3) to detect somatic prioritised single-nucleotide variants. This cohort was integrated with 86 patients from the ACC-TCGA series bearing point-mutations in the same genes and their combinations identified by our panel. Primary endpoints of the analysis on the total cohort (113 patients) were overall survival (OS) and progression-free survival (PFS), and hazard ratio (HR) for the different alterations grouped by the signalling pathways/combinations affected.

Results

Different PFS, OS, and HR were associated to the different pathways/combinations, being NF1 + TP53 and Wnt/β-catenin + Rb/p53 combined mutations the most deleterious, with a statistical significance for progression HR which is retained only in low-(I/II) stages—NF1 + TP53 combination: HR = 2.96[1.01-8.69] and HR = 13.23[3.15-55.61], all and low stages, respectively; Wnt/β-catenin + Rb/p53 combined pathways: HR = 6.47[2.54-16.49] and HR = 16.24[3.87-68.00], all and low-stages, respectively.

Conclusions

A simplified targeted-NGS approach seems the best routinely applicable first step towards somatic genetic characterisation of ACC for prognostic assessment. This approach proved to be particularly promising in low-stage cases, suggesting the need for more stringent surveillance and personalised treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adrenal Cortex NeoplasmsHigh-Throughput Nucleotide SequencingAdrenocortical CarcinomaHumansMaleFemaleMiddle AgedAdultRetrospective StudiesAgedMutationPrognosisYoung AdultAdolescentAged, 80 and over

Stichwörter der Autor:innen

ACCACC-TCGAgeneticsmolecular oncologyprogression-free survivalroutine analysissomatic mutational profiletargeted-NGS

Autor:innen und Institutionen

  • Department of Experimental and Clinical Medicine, University of Florence, 50139 Florence, Italy.
  • European Network for the Study of Adrenal Tumours (ENSAT) Centre of Excellence, University of Florence, 50139 Florence, Italy.
  • Department of Experimental and Clinical Biomedical Sciences, Endocrinology Section, University of Florence, 50139 Florence, Italy.
  • Centro di Ricerca e Innovazione sulle Patologie Surrenaliche, AOU Careggi, 50139 Florence, Italy.
  • Azienda Ospedaliero-Universitaria Careggi, (AOUC), 50139 Florence, Italy.
  • Medical Genetics, Azienda Ospedaliera di Rilievo Nazionale (A.O.R.N.) Cardarelli, Padiglione, 80131 Naples, Italy.

ORCID-Profile: Letizia Canu, Michaela Luconi

Förderung

  • Italian Ministry of University and Research
  • PRIN program
  • Progetti di Ricerca di Rilevante Interesse Nazionale 2022
  • Associazione Italiana Ricerca sul Cancro AIRC

Zitieren

APA

Cioppi, F., Cantini, G., Ercolino, T., Chetta, M., Zanatta, L., Nesi, G., Mannelli, M., Maggi, M., Canu, L., & Luconi, M. (2024). Targeted Next Generation Sequencing molecular profiling and its clinical application in adrenocortical cancer. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvae077

Vancouver

Cioppi F, Cantini G, Ercolino T, Chetta M, Zanatta L, Nesi G, et al. Targeted Next Generation Sequencing molecular profiling and its clinical application in adrenocortical cancer. European Journal of Endocrinology. 2024. doi:10.1093/ejendo/lvae077

BibTeX
@article{Cioppi2024,
  author = {Cioppi, Francesca and Cantini, Giulia and Ercolino, Tonino and Chetta, Massimiliano and Zanatta, Lorenzo and Nesi, Gabriella and Mannelli, Massimo and Maggi, Mario and Canu, Letizia and Luconi, Michaela},
  title = {Targeted Next Generation Sequencing molecular profiling and its clinical application in adrenocortical cancer},
  journal = {European Journal of Endocrinology},
  year = {2024},
  doi = {10.1093/ejendo/lvae077}
}
Kostenlos starten →